Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Investing Activities (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Cash from Investing Activities data on record, last reported at -$60.6 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 69.77% year-over-year to -$60.6 million; the TTM value through Dec 2025 reached -$70.3 million, up 43.7%, while the annual FY2025 figure was -$70.3 million, 43.7% up from the prior year.
  • Cash from Investing Activities reached -$60.6 million in Q4 2025 per AMPH's latest filing, down from -$19.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $15.2 million in Q1 2024 and bottomed at -$508.6 million in Q2 2023.
  • Average Cash from Investing Activities over 5 years is -$45.3 million, with a median of -$10.5 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: crashed 44899.56% in 2023, then skyrocketed 340.6% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$12.0 million in 2021, then surged by 98.08% to -$229000.0 in 2022, then plummeted by 44899.56% to -$103.0 million in 2023, then surged by 65.38% to -$35.7 million in 2024, then crashed by 69.77% to -$60.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$60.6 million in Q4 2025, -$19.6 million in Q3 2025, and -$625000.0 in Q2 2025.